Integrative multi-omics analysis and machine learning refine global histone modification features in prostate cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.A new score (CMLHMS) classifies prostate cancer (PCa) into subtypes based on histone modifications, revealing distinct therapeutic vulnerabilities for better treatment strategies.
Area Of Science
- Oncology
- Molecular Biology
- Genomics
Background
- Prostate cancer (PCa) is a leading cause of male cancer mortality.
- Tumor heterogeneity and treatment resistance are key challenges in PCa management.
- Histone modifications' role in PCa progression and therapy resistance is not well understood.
Purpose Of The Study
- To investigate histone modification-driven heterogeneity in prostate cancer.
- To develop a machine learning model for classifying PCa subtypes.
- To identify potential therapeutic targets based on identified subtypes.
Main Methods
- Integrative multi-omics analysis and machine learning.
- Development of the Comprehensive Machine Learning Histone Modification Score (CMLHMS).
- Single-cell RNA sequencing and drug sensitivity analysis.
Main Results
- CMLHMS classifies PCa into high and low subtypes with distinct biological and clinical features.
- High-CMLHMS tumors show increased proliferation, metabolic activity, and link to castration-resistant PCa (CRPC).
- Low-CMLHMS tumors exhibit stress-adaptive and immune-regulatory phenotypes; distinct drug sensitivities were observed for each subtype.
Conclusions
- The CMLHMS model effectively stratifies PCa, offering insights into heterogeneity.
- This study identifies novel therapeutic strategies for advanced PCa.
- Findings contribute to precision oncology for prostate cancer patients.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.